New Light-Based scanner could spot cancer without needles
NCT ID NCT05488483
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether a new imaging technique called multispectral optoacoustic tomography (MSOT) can visualize breast cancer and melanoma tumors. Twelve participants will have MSOT scans before their standard biopsy or treatment. The goal is to see if MSOT can detect tumors and measure oxygen levels, which might help improve cancer diagnosis in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Multispectral Optoacoustic Tomography (MSOT) imaging
What this could lead to
If successful, this could lead to a new, non-invasive way to detect and monitor tumors without radiation or contrast dyes.
What could go wrong
This is a very small feasibility study with only 12 participants, so results may not apply to everyone. The technology is still experimental and may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Helmholtz Institute (Data Analysis Only)
Munich, Germany
-
Memorial Sloan - Kettering Cancer Center
New York, New York, 10021, United States
-
Memorial Sloan Kettering Bergen (Consent only )
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)
Commack, New York, 11725, United States